--- title: "Everest Medicines Secures Exclusive License to Commercialize MT1013 in Greater China and Asia" description: "Everest Medicines Limited has secured an exclusive license from Shaanxi Micot Pharmaceutical Technology Co., Ltd. to commercialize MT1013 in Greater China and other Asian markets. MT1013 is a first-in" type: "news" locale: "en" url: "https://longbridge.com/en/news/274881664.md" published_at: "2026-02-04T23:01:42.000Z" --- # Everest Medicines Secures Exclusive License to Commercialize MT1013 in Greater China and Asia > Everest Medicines Limited has secured an exclusive license from Shaanxi Micot Pharmaceutical Technology Co., Ltd. to commercialize MT1013 in Greater China and other Asian markets. MT1013 is a first-in-class dual-targeting receptor agonist polypeptide aimed at treating secondary hyperparathyroidism, with potential expansion into chronic kidney disease-mineral and bone disorder and osteoporosis. This collaboration will enhance Everest Medicines’ nephrology portfolio. Everest Medicines Limited announced that its wholly-owned subsidiary, Everest Medicines (China) Co., Ltd., has entered into an agreement with Shaanxi Micot Pharmaceutical Technology Co., Ltd. Under the agreement, Micot has granted Everest Medicines an exclusive license to commercialize MT1013 in Greater China and other Asian markets. MT1013 is described as a first-in-class dual-targeting receptor agonist polypeptide developed primarily for secondary hyperparathyroidism, with plans to expand into indications such as chronic kidney disease-mineral and bone disorder and osteoporosis. The collaboration is expected to broaden Everest Medicines’ nephrology portfolio. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Everest Medicines Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260205-12015013), on February 04, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) ### Related Stocks - [BBH.US - VanEck Biotech ETF](https://longbridge.com/en/quote/BBH.US.md) - [588250.CN - Penghua SSE STAR Biology and Medicine ETF](https://longbridge.com/en/quote/588250.CN.md) - [512010.CN - E Fund CSI 300 Health Care ETF](https://longbridge.com/en/quote/512010.CN.md) - [IBBQ.US - Invesco Nasdaq Biotechnology ETF](https://longbridge.com/en/quote/IBBQ.US.md) - [BIB.US - Proshares Ultra Nasdaq Biotech](https://longbridge.com/en/quote/BIB.US.md) - [560600.CN - Founder Fubon CSI Medicine and Medical Device Innovation ETF](https://longbridge.com/en/quote/560600.CN.md) - [SBIO.US - ALPS Medical Breakthrough](https://longbridge.com/en/quote/SBIO.US.md) - [159859.CN - Tianhong CNI BIOMEDICINE ETF](https://longbridge.com/en/quote/159859.CN.md) - [513700.CN - Penghua CSI HK Connect Health Care Composite ETF](https://longbridge.com/en/quote/513700.CN.md) - [IBB.US - iShares Biotechnology ETF](https://longbridge.com/en/quote/IBB.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | 中国生物制药称，国家药品监督管理局已批准 Benmelstobart 注射液上市 | 中国生物制药表示，国家药品监督管理局已批准 Benmelstobart 注射剂上市 | [Link](https://longbridge.com/en/news/276024005.md) | | Insulet 公司（NASDAQ：PODD）被分析师给予 “适度买入” 的平均评级 | Insulet Corporation（纳斯达克代码：PODD）获得了 24 位分析师的平均评级为 “适度买入”，其中 20 位推荐买入，4 位建议持有。12 个月的平均目标价为 374.10 美元。最近的分析师报告包括 Weiss Rat | [Link](https://longbridge.com/en/news/276105237.md) | | Biocon 计划通过推出仿制减肥药来推动收入增长 | Biocon 计划通过全球推出包括诺和诺德的 Wegovy 和利拉鲁肽在内的仿制减肥药，实现高双位数的收入增长。该公司计划在下一个财年在美国推出仿制利拉鲁肽，并在加拿大推出 Wegovy，同时由于激烈的价格竞争和监管障碍，对进入印度市场持谨 | [Link](https://longbridge.com/en/news/276028392.md) | | ImmunityBio 成立沙特子公司以推动中东和北非地区的扩张 | ImmunityBio Inc. 在沙特阿拉伯成立了一家全资子公司，以增强其在中东和北非的业务。这家新办公室将促进监管提交、商业发布和临床开发，旨在更好地支持当地医生和卫生系统 | [Link](https://longbridge.com/en/news/276114859.md) | | 法国工业信贷银行出售了 140,000 股 Alumis Inc.的股票，股票代码为$ALMS | 信用工业与商业银行减少了对 Alumis Inc.（NASDAQ:ALMS）36.2% 的持股，在第三季度出售了 140,000 股，目前持有 247,002 股，价值 986,000 美元。其他机构投资者也调整了他们的持仓，其中 MIRA | [Link](https://longbridge.com/en/news/276046269.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.